Enhancements Offer a More Seamless Experience and Pave the Way for ‘Precision Engagement’ Healthcare

Palo Alto, CA, USA – May 9, 2023 – Glooko, Inc., today announced the redesign of their award-winning mobile app for its connected care platform, that will provide a more streamlined experience for its mobile users. The sleek, modern design makes it even easier to navigate all of Glooko’s robust mobile app features for better diabetes management. When connected to the user’s healthcare providers (HCPs), the latest version of the app also includes enhancements that will allow for personalization of their care via an upcoming advancement called ‘Precision Engagement.’

“As a global leader in Connected Care, Glooko has been at the forefront of leveraging our mobile app for improved diabetes management,” said Ed Marshall, Chief Product Officer at Glooko. “With today’s increasingly fragmented healthcare delivery, it’s a privilege and a huge opportunity for Glooko to strengthen the connections between patients and their care team. This is an important investment Glooko is making to continue to upgrade the user experience, making it more convenient, more personalized, and ultimately more impactful.”

While developing the new app experience, user engagement was key. The app redesign was informed by feedback from Glooko users who will see visual improvements and a new unified design as part of an overall evolution of the digital health platform.

The enhancements include the following:

• User Interface and Data Visualization -> The new mobile app design makes it easier for users to organize their data in one place and share with their HCPs; i.e. glucose trends, insulin doses, food, exercise, weight and blood pressure. Users will see their health care team or clinic name at the top of the screen and can click to share reports with their HCP and see all active care teams in one place.

• Home Screen -> New navigation helps users access popular features efficiently like food logging and sharing data with care teams, available with one scroll and featuring the most current data on their health. The home screen one-scroll feature also includes: profile settings, care team name, goals, history, connected devices, button to add new event, charts and graphs with two weeks of data.

• Onboarding Process -> For users new to Glooko, the onboarding experience is now easier; the reimagined onboarding process is guided and walks new users through it in a simple, “bite-sized” way that allows them to do it at their own pace. New users are guided to more easily: select a glucose device, select an insulin device, complete their profile.

• Precision Engagement -> The new design was built with the specific ability to house Glooko’s upcoming functionality of ‘Precision Engagement.’ Precision Engagement tools leverage environmental, behavioral, and physiologic data from medical devices, wearables, consumer devices, and smartphones to better understand an individual’s unique preferences, habits, and environment. With these unique insights, Glooko detects the right moments and aims to deliver personalized recommendations to help influence behavior. More to come from Glooko on Precision Engagement in the near future.

The updates coincide with other major milestones for Glooko:

• The mobile app is available globally in 30+ countries and 20+ languages and growing.

• Glooko is now compatible with over 200 diabetes and biometric devices worldwide, the largest compatibility of any connected care platform.

• Over 8,000 clinics globally provide care to patients using Glooko.

• Glooko is the only connected care platform that is compatible with all the major smart insulin pens and pharmaceutical manufacturers.

About Glooko
Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations.

Glooko.com LinkedIn.com Twitter Instagram Facebook

###

Media Contact
Tanya Rodante
Director of Global Communication
[email protected]

La colaboración brinda atención personalizada para la diabetes

Palo Alto, CA (EE. UU.) – 11 de abril de 2023: Glooko, Inc. ha anunciado hoy una nueva colaboración global con Hedia. Con esta colaboración, integra su tecnología en la plataforma para el control de la diabetes de Glooko para profesionales de la salud y personas con diabetes. Gracias a esta colaboración, se creará una solución interoperativa que aúna atención conectada, supervisión remota de pacientes y tecnologías terapéuticas digitales para mejorar el acceso de las personas con diabetes tipo 1 y tipo 2 que requieren consejos de administración de la insulina en bolo.

Con la plataforma de Glooko, los pacientes actualmente pueden compartir sus datos de diabetes con sus profesionales sanitarios, incluidas las lecturas de glucemia, la dosis de insulina, los alimentos y los carbohidratos, la actividad física, la tensión arterial y el peso. Con la integración de Hedia Diabetes Assistant, las personas con diabetes podrán recibir consejos sobre la dosificación de insulina en bolo, lo que proporcionará atención personalizada y acabará con la necesidad de calcular manualmente las dosis de insulina necesarias. Además, si se utiliza con plumas de insulina conectadas*, la solución integrada ofrece un gran nivel de visibilidad a los profesionales sanitarios que tratan a pacientes con múltiples inyecciones diarias (MDI). Esta integración mejora las capacidades de supervisión remota de pacientes de Glooko y es compatible con consultas virtuales para pacientes con MDI.

“Nos complace enormemente nuestra colaboración con Hedia, que nos permite crear esta innovación impulsada por algoritmos para la atención médica personalizada de pacientes diabéticos y sus equipos de atención médica”, comenta Russ Johannesson, director ejecutivo de Glooko. “Los fiables datos clínicos que respaldan la eficacia de Hedia demuestran que esta podría ser una alternativa viable para los pacientes que no pueden acceder a las bombas de insulina. Con esta asociación se demuestra cómo la interoperabilidad ofrece a las personas con diabetes las herramientas óptimas para facilitar el control de su enfermedad y mejorar su salud, como la estabilidad de los niveles de glucemia”.

Peter Lucas, director ejecutivo de Hedia, afirma: “Estamos encantados de que Glooko, una empresa con una amplia red clínica, sea nuestro socio en salud digital. Además de nuestra gran evidencia clínica, una de las cuestiones clave que tenemos en cuenta al crear nuestra tecnología es el cumplimiento de las normativas y la ciberseguridad. Glooko ha demostrado su fortaleza en estas áreas con varias certificaciones de terceros y eso es un factor clave de nuestra asociación. La designación de dispositivos médicos de clase IIb de Hedia garantiza que se proporcionen las mejores soluciones a los pacientes y a sus equipos de atención.”

Se espera que el lanzamiento inicial europeo de la integración tenga lugar en el cuarto trimestre de 2023 y el primer trimestre de 2024.

*La función de pluma conectada solo está disponible en la UE.

Acerca de Glooko
Glooko mejora los resultados de salud de las personas con enfermedades crónicas a través de su plataforma de atención personalizada, inteligente y conectada. Nuestras tecnologías, de eficacia probada, mejoran la vida de las personas al revolucionar la conexión entre pacientes y proveedores, impulsando el compromiso y la adherencia de los pacientes a través de los tratamientos digitales y acelerando la velocidad de los ensayos clínicos. Glooko trabaja en más de 30 países y en más de 8000 clínicas.

Glooko.com LinkedIn.com Twitter Instagram Facebook

Acerca de Hedia
Hedia es una empresa líder en productos terapéuticos digitales para la diabetes, comprometida con ayudar a las personas con diabetes dependiente de la insulina a controlar su enfermedad. Facilitar la vida a las personas con diabetes ha sido el motor desde la creación de Hedia Diabetes Assistant y la solución está disponible hoy en 11 países. Según los hábitos de la persona con diabetes y los datos personalizados, nuestra aplicación para la diabetes genera recomendaciones de insulina a partir de muchos aspectos del control de la diabetes, como el registro de las lecturas de glucemia, el seguimiento de la insulina activa, la medición de carbohidratos, el cálculo de la dosis de insulina, el seguimiento de la actividad y el registro de los niveles de cetonas en sangre.

Hedia.com LinkedIn

###

Contacto de prensa
Tanya Rodante
Director of Global Communication
[email protected]

Une collaboration qui permet aux personnes atteintes de diabète de bénéficier de soins personnalisés

Palo Alto, Californie, États-Unis – 11 avril 2023 – Glooko, Inc. a annoncé aujourd’hui un nouveau partenariat mondial avec Hedia, intégrant la technologie de cette dernière à ses plateformes de gestion du diabète pour les professionnels de santé et les personnes atteintes de diabète. Cette collaboration permettra de proposer des solutions interopérables intégrant les soins connectés, le suivi à distance des patients et les technologies thérapeutiques numériques afin d’améliorer l’accès des personnes atteintes de diabète de type 1 et de type 2 à des conseils sur la titration des bolus d’insuline.

Avec la plateforme de Glooko, les patients ont actuellement la possibilité de partager leurs données sur le diabète avec leurs professionnels de santé, notamment les mesures de glycémie, les doses d’insuline, l’alimentation et les glucides, l’activité physique, la pression artérielle et le poids. Grâce à l’intégration de l’Assistant Diabète Hedia, les personnes atteintes de diabète pourront recevoir des conseils sur la titration des bolus d’insuline, ce qui permettra de personnaliser les soins et de réduire la charge liée au calcul manuel des doses d’insuline requises. En outre, lorsqu’elle est utilisée avec des stylos à insuline connectés*, la solution intégrée apporte une meilleure visibilité aux professionnels de santé qui prennent en charge les patients sous traitement par injections quotidiennes multiples. Cette intégration améliore le suivi à distance des patients au sein des plateformes de Glooko et permet des téléconsultations pour les patients sous shéma basal-bolus.

« Nous sommes très heureux de collaborer avec Hedia et de pouvoir proposer aux patients atteints de diabète et à leurs équipes de soignants des soins personnalisés grâce à cette innovation basée sur des algorithmes », a déclaré Russ Johanneson, PDG de Glooko. « Les données cliniques fiables qui étayent l’efficacité d’Hedia démontrent qu’il pourrait s’agir d’une excellente alternative pour les patients qui n’ont pas accès aux pompes à insuline. Ce partenariat montre comment l’interopérabilité offre aux personnes atteintes de diabète les outils optimaux disponibles pour faciliter la prise en charge de leur maladie et améliorer leur santé, notamment la stabilité des taux de glycémie. »

Peter Lucas, PDG d’Hedia, a déclaré : « Nous sommes ravis que Glooko, une entreprise dotée d’un réseau aussi étendu, soit notre partenaire en matière de santé numérique. Outre nos solides preuves cliniques, l’une des questions clés que nous prenons en compte lors de l’élaboration de notre technologie est la conformité réglementaire et la cybersécurité. Glooko a démontré sa force dans ces domaines avec plusieurs certifications tierces et c’est un élément clé de notre partenariat. La désignation de dispositif médical de classe IIb d’Hedia garantit que les meilleures solutions sont fournies aux patients et à leurs équipes de soignants. »

Le lancement initial de l’intégration en Europe est prévu au quatrième trimestre 2023 et au premier trimestre 2024..

*La fonctionnalité stylo connecté n’est disponible que dans l’UE.

À propos de Glooko
Glooko améliore les résultats de santé des personnes souffrant de maladies chroniques grâce à sa plateforme de soins personnalisée, intelligente et connectée. Nos technologies éprouvées améliorent la vie des patients en révolutionnant le lien entre les patients et les prestataires de soins, en favorisant l’engagement et l’adhésion des patients via des thérapies numériques et en accélérant l’exécution des essais cliniques. Glooko est déployé dans le monde entier, dans plus de 30 pays et plus de 8 000 sites cliniques.

Glooko.com LinkedIn.com Twitter Instagram Facebook

À propos d’Hedia
Hedia est une entreprise leader dans le domaine des thérapies numériques pour le diabète, qui s’engage à aider les personnes atteintes de diabète insulinodépendantes à prendre le contrôle de leur maladie. Faciliter la vie avec le diabète a été la motivation dès le début de la création de l’Assistant Diabète Hedia et la solution est aujourd’hui disponible dans 11 pays. En fonction des habitudes de la personne atteinte de diabète et des données personnalisées, notre application diabète génère des recommandations en matière d’insuline en prenant en compte de nombreux aspects de la gestion du diabète, tels que l’enregistrement des mesures de glycémie, le suivi de l’insuline active, la mesure des glucides, le calcul de la titration des doses d’insuline, le suivi de l’activité et l’enregistrement des corps cétoniques dans le sang.

Hedia.com LinkedIn

###

Contact pour les médias
Tanya Rodante
Director of Global Communication
[email protected]

Collaboration Provides People with Diabetes Personalized Care

Palo Alto, CA, USA – April 11, 2023 – Glooko, Inc., announced today a new Global partnership with Hedia, integrating its technology into Glooko’s diabetes management platforms for healthcare providers and people with diabetes. The collaboration will provide an interoperable solution that brings together connected care, remote patient monitoring and digital therapeutic technologies to enhance access for people with Type 1 and Type 2 diabetes requiring bolus insulin dosing advice.

With the Glooko platforms, patients currently have the ability to share their diabetes data with their healthcare providers (HCPs), including blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure and weight. With the integration of Hedia Diabetes Assistant, people with diabetes will be able to receive bolus insulin dosing advice, which will provide personalized care and reduce the burden of manually calculating required insulin doses. In addition, when used in conjunction with connected insulin pens*, the integrated solution facilitates a high level of visibility for HCPs who are managing patients on multiple daily injection (MDI) therapy. This integration enhances the capabilities of Glooko’s remote patient monitoring (RPM) and supports virtual consultations for MDI patients.

“We are very pleased to partner with Hedia to offer this algorithm-driven innovation for personalized healthcare for diabetes patients and their healthcare teams,” stated Russ Johannesson, CEO of Glooko. “The robust clinical data supporting Hedia’s efficacy demonstrates this could be a viable alternative for patients who are not able to access insulin pumps. This partnership shows how interoperability gives people with diabetes the optimal tools available to ease the management of their condition and enhance health outcomes such as the stability of blood glucose levels.”

Peter Lucas, CEO of Hedia said, “We are thrilled to call Glooko, a company with such an extensive clinical network, our partner in digital health. In addition to our strong clinical evidence, one of the key issues we consider when building our technology is regulatory compliance and cybersecurity. Glooko has demonstrated their strength in these areas with multiple third-party certifications and that’s a key driver behind our partnership. Hedia’s Class IIb medical device designation ensures that the best solutions are being provided to patients and their care teams.”

The initial European launch of the integration is expected in the fourth quarter of 2023 and first quarter of 2024.

*The connected pen feature is available only in the EU.

About Glooko
Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platforms. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations.

Glooko.com LinkedIn.com Twitter Instagram Facebook

About Hedia
Hedia is a leading digital therapeutics company within diabetes, committed to help people with insulin-dependent diabetes gain control of their condition. Making life with diabetes easier has been the incentive from the beginning of building Hedia Diabetes Assistant and the solution is today available in 11 countries. Based on habits of the individual person with diabetes and personalized input, our diabetes app generates insulin recommendations by taking many aspects of diabetes management into account – such as recording blood glucose readings, keeping track of active insulin, measuring carbs, calculating an insulin dosage, keeping track of activity, recording blood ketones.

Hedia.com LinkedIn

###

Media Contact
Tanya Rodante
Director of Global Communication
[email protected]

Zusammenarbeit bietet Menschen mit Diabetes eine individuelle Versorgung

Palo Alto, Kalifornien, USA – 11 April 2023 – Glooko Inc. kündigte heute eine neue globale Partnerschaft mit Hedia an. Dieser Zusammenschluss führt dazu, dass Hedias Technologie in Glookos Plattform für Diabetesmanagement für Praxen/Kliniken und Menschen mit Diabetes integriert wird. Die Zusammenarbeit führt zu einer interoperablen Lösung, durch die vernetzte Versorgung, Patientenbetreuung aus der Ferne und digitale Therapietechnologien vereint werden. Dadurch wird der Zugang für Patienten mit Typ-1- und Typ-2-Diabetes, die Dosierungsangaben für Bolusinsulin benötigen, verbessert.

Mit der Glooko-Plattform haben Patienten derzeit die Möglichkeit, ihre Diabetesdaten mit ihren Gesundheitsdienstleistern zu teilen, darunter Blutzuckermesswerte, Insulindosen, Nahrungsmittel und Kohlenhydrate, körperliche Aktivität, Blutdruck und Gewicht. Durch die Integration des Hedia Diabetes Assistant erhalten Menschen mit Diabetes eine Dosierungsempfehlung für Bolusinsulin. Dies ermöglicht eine individuelle Versorgung und sorgt für einen geringeren manuellen Berechnungsaufwand der erforderlichen Insulindosen. Darüber hinaus verbessert die integrierte Lösung in Verbindung mit smarten Insulinpens* die Sichtbarkeit für Praxen/Kliniken, die Patienten betreuen, die mehrfach täglich Insulininjektionen benötigen. Diese Integration verbessert Glookos Möglichkeiten der Betreuung der Patienten von zu Hause aus und unterstützt virtuelle Termine für Patienten, die mehrfach täglich Insulininjektionen benötigen.

„Wir freuen uns sehr, gemeinsam mit Hedia diese algorithmusgesteuerte Innovation für eine individuelle Gesundheitsversorgung für Menschen mit Diabetes und deren Gesundheitsteams anbieten zu können“, so Russ Johannesson, CEO von Glooko. „Die robusten klinischen Daten, die die Wirksamkeit von Hedia belegen, zeigen, dass dies eine mögliche Alternative für Patienten sein könnte, die keinen Zugang zu Insulinpumpen haben. Diese Partnerschaft zeigt, wie die Interoperabilität Menschen mit Diabetes die optimalen Hilfsmittel zur Verfügung stellt, um die Behandlung ihrer Erkrankung zu erleichtern und die gesundheitlichen Perspektiven wie die Stabilität des Blutzuckerspiegels zu verbessern.“

Peter Lucas, CEO von Hedia, sagte: „Wir freuen uns, Glooko, ein Unternehmen mit einem so umfangreichen klinischen Netzwerk, als Partner im Bereich digitale Gesundheit bezeichnen zu können. Zusätzlich zu unseren fundierten klinischen Daten sind die Einhaltung gesetzlicher Vorschriften und die Cybersicherheit zwei der wichtigsten Punkte, die wir bei der Entwicklung unserer Technologie berücksichtigen. Glooko hat seine Stärke in diesen Bereichen mit mehreren Drittanbieter-Zertifizierungen unter Beweis gestellt, und das ist ein wichtiger Faktor für unsere Partnerschaft. Die Kennzeichnung von Medizinprodukten der Klasse IIb durch Hedia stellt sicher, dass den Patienten und ihren Behandlungsteams die besten Lösungen zur Verfügung stehen.“

Die europäische Markteinführung der Integration wird für das vierte Quartal 2023 und das erste Quartal 2024 erwartet.

*Die Funktion der verbundenen Pens ist nur in der EU verfügbar.

Über Glooko
Glooko verbessert die gesundheitlichen Perspektiven von Menschen mit chronischen Erkrankungen durch eine personalisierte, intelligente und vernetzte Versorgungsplattform. Unsere bewährten Technologien sorgen für bessere Lebensqualität, indem sie die Verbindung zwischen Patienten und Anbietern revolutionieren, die Patientenbindung und Therapietreue über digitale Therapeutika fördern und klinische Studien beschleunigen. Glooko ist weltweit in mehr als 30 Ländern und an über 8.000 klinischen Standorten vertreten.

Glooko.com LinkedIn.com Twitter Instagram Facebook

Über Hedia
Hedia ist ein führendes Unternehmen für digitale Therapeutika im Bereich Diabetes und hat sich zum Ziel gesetzt, Menschen mit insulinabhängigem Diabetes dabei zu helfen, ihre Erkrankung unter Kontrolle zu bringen. Der Anreiz für die Entwicklung des Hedia Diabetes Assistant war es, das Leben mit Diabetes zu erleichtern. Die Lösung ist heute in 11 Ländern verfügbar. Basierend auf den Gewohnheiten der einzelnen Person mit Diabetes und personalisiertem Input generiert unsere Diabetes-App Insulinempfehlungen, die viele Aspekte des Diabetesmanagements berücksichtigen – wie die Aufzeichnung der Blutzuckermesswerte, den Überblick über das aktive Insulin, die Messung von Kohlenhydraten, die Berechnung einer Insulindosis, den Überblick über Aktivitäten und das Aufzeichnen von Blutketonen.

Hedia.com LinkedIn

###

Medienkontakt
Tanya Rodante
Director of Global Communication
[email protected]

PALO ALTO, CA, February 23, 2023 – Glooko Inc. (“Glooko”), today announced that they have entered into a partnering agreement with Sanofi to increase their support of people living with diabetes and healthcare professionals, by integrating SoloSmart with the Glooko® platform. SoloSmart is a single piece add-on connected device intended for use with SoloStar and DoubleStar insulin injection pens which records the insulin dose, date and time of injection and allows for visualization of the data in the Glooko app, that patients can share with healthcare professionals for connected care in diabetes management. At this time, SoloSmart is not approved in the US.

Through Glooko’s global footprint of over 8,000 clinics, Sanofi aims to increase the accessibility of digital solutions to people with diabetes in each of the given countries where SoloSmart will be made available. The SoloSmart cap is currently undergoing integration with the Glooko platform and will gradually roll out across several countries starting later in 2023. The combined solution will be made available in English and local languages. As part of the global agreement, Glooko and Sanofi contemplate the option to further expand the launch of the combined technologies beyond the initial geographic scope.

“We are very pleased to announce our partnership with Sanofi, as this agreement represents the first substantial digital health collaboration between our two companies” says Russ Johannesson, CEO, Glooko. “Glooko is the first global diabetes data management platform to launch with SoloSmart, something our team is particularly proud of. This will allow us to further expand our global reach aiming to provide best-in-class technologies that can benefit the lives of people with diabetes.”

“At Sanofi, we believe that we will deliver value to people living with diabetes by building an ecosystem with local and global partners. With Biocorp, SoloSmart’s manufacturer; Glooko, a leading digital health solution that supports patients and health care partners, and local partners, we aim to improve daily management for individuals living with diabetes,” says Jared Josleyn, Global Head of Digital Healthcare, Sanofi. “For 100 years, Sanofi has been at the forefront of managing diabetes. We continue to build on this heritage with a vision and commitment to help transform diabetes care for 537 million people living with diabetes around the world.”

Once SoloSmart is integrated with the Glooko platform, SoloStar and DoubleStar pen users will have the ability to add the tracking of insulin dosing and timing to the functionality of Glooko to improve their insulin management and tracking. Combining SoloSmart and Glooko will help users visualize the correlation between insulin dose injected and blood glucose values. The insulin tracking data can be linked to other important features of the Glooko mobile app like food tracking, exercise metrics, weight and blood pressure to create actionable insights to help people with diabetes approach care in an even more personalized way.

About Glooko
Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations.

Glooko.com LinkedIn.com Twitter Instagram FaceBook

###

Media Contact
Tanya Rodante
Director of Global Communication
[email protected]

Connected Care Industry Leader Achieves Internationally Recognized Security Certification

PALO ALTO, CA, February 6, 2023 – Glooko Inc. (“Glooko”), a leading provider of intelligent, connected care solutions for people with chronic conditions, today announced that it has received ISO 27001 certification for its data management and remote patient monitoring (RPM) platforms.

“Achieving this internationally recognized standard is evidence of Glooko’s commitment to best-in-class business processes and security operations. This certification enables us to demonstrate to our current and future customers that we take the protection of health data seriously,” said Glooko Chief Executive Officer, Russ Johannesson.

ISO 27001 is an international compliance framework set by the International Organization for Standardization (ISO) and the International Electrotechnical Commission (IEC), and is the international security standard for protecting customer information.

Glooko’s independent, third-party ISO 27001 auditor is SGS-TÜV Saar, a joint venture of TÜV Saarland, a German certification multinational founded in 1871, and Swiss-based SGS Group, the world’s leading testing, inspection and certification company. Their certification confirms that Glooko has all the required controls in place for people, systems, and processes to ensure the security of customer data and the company’s software platforms.

Compliance with this internationally recognized standard confirms that Glooko’s security management program is comprehensive and follows gold-standard practices. By achieving ISO 27001 (Glooko also possesses SOC 2 Type II and HITRUST security certifications) the company can assure customers that attested measures are in place to secure patient health data from unauthorized access or compromise.

“This certification allows Glooko to meet compliance expectations for customers and partners who are looking for independent assurance of our security practices,” said Prakash Menon, Chief Technology Officer for Glooko. “After going through a 12-month implementation and auditing process, we’ve fully implemented all ISO 27001 processes and controls. Customers should expect this level of commitment from any vendor that handles their data and we are happy to be able to provide this assurance to them.”

Learn more: https://glooko.com/trust-privacy/

About Glooko
Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations. For more information, please visit glooko.com.

###

Media Contact
Tanya Rodante
Director of Global Communication
[email protected]

Achieving Security Certifications Demonstrates the Company’s Continued Commitment to Securing Patient Health Data

PALO ALTO, CA, November 3, 2022 – Glooko Inc. (“Glooko”), today announced achieving SOC 2 Type II certification and renewal of HITRUST certification for Glooko®, its industry leading connected care platform for people with chronic conditions. Glooko has a longstanding commitment to protecting sensitive data and information, and understands the growing importance in healthcare to meet complex compliance and privacy requirements.

Developed by HITRUST, the standards and certification body that helps organizations achieve information security, privacy, and regulatory compliance goals through comprehensive and innovative solutions, the HITRUST Risk-based, 2-year (r2) Certification is the industry gold standard, combining security standards set by HIPAA, NIST, COBIT, and many more. Glooko’s HITRUST recertification places the company in an elite group of organizations worldwide, proving that its attested security controls meet these standards of protecting patient health data.

Along with the two-year HITRUST recertification, the Company has achieved SOC 2 Type II certification, which follows its SOC 2 Type I certification achieved late last year. This extensive reporting standard provides independent validation from a sophisticated, Silicon Valley based third-party auditing firm that Glooko has all the required controls in place for their employees, systems and processes to ensure the security of customers’ data, its software and company. These accredited 3rd-party auditors have certified that Glooko’s attested security controls and policies work extremely well in securing patient health data.

“Organizations like ours are continually under pressure to meet complex compliance and privacy requirements that include technical and process elements such as NIST and ISO,” said Prakash Menon, Chief Technology Officer at Glooko. “We are pleased to demonstrate to our customers our commitment to the highest standards for data protection and information security by achieving these rigorous third-party certifications.”

“In today’s ever-changing threat landscape, HITRUST is continually innovating to find new and creative approaches to address challenges,” said Jeremy Huval, Chief Innovation Officer, HITRUST. “Glooko’s HITRUST Risk-based, 2-year Certification is evidence that they are at the forefront of industry best practices for information risk management and compliance.”

For more information: https://glooko.com/trust-privacy/

About Glooko
Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations. For more information, please visit glooko.com.

###

Media Contact
Tanya Rodante
Director of Global Communications
[email protected]

Company Honored With a Gold for News Coverage for its Thought Leadership on Remote Patient Monitoring

PALO ALTO, CA, August 23, 2022 – Glooko Inc. (“Glooko”), a leading provider of intelligent, connected care solutions and remote patient monitoring (RPM) for people with chronic conditions, today announced that the Company earned gold honors for their work in thought leadership and earned media placements.

The dotCOMM Awards is administered and judged by the Association of Marketing and Communication Professionals (AMCP), one of the largest, oldest and most respected evaluators of creative work in the marketing and communication industry. Since its inception in 1994, AMCP has judged over 200,000 entries from throughout the world.

“We’re honored to be recognized by the dotCOMM community for our thought leadership in connected care technology and specifically, remote patient monitoring,” said Zach Henderson, Chief Commercial Officer at Glooko. “This award is a testament to our commitment to increasing awareness and education among healthcare providers on the benefits of connected, remote care, and ultimately improving the lives of people with chronic conditions through these innovations.”

The gold award recognition acknowledges the level of the Company’s 2021 coverage in healthcare media and digital health publications, bylined by Glooko’s Chief Medical Officer, Dr. Mark Clements, as a contributing author.

Glooko’s connected care platform, and specifically its remote patient monitoring solution, has seen record adoption since 2020.

About Glooko
Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations. For more information, please visit glooko.com.

About dotCOMM Awards
The dotCOMM Awards is an international competition that celebrates brilliance in web creativity and digital communication. The competition is unique in that it reflects the role of creatives in the dynamic web that is transforming how we market and communicate products and services. The awards are administered and judged by the Association of Marketing and Communication Professionals (AMCP), a leading organization of evaluators of creative work in the ever-evolving marketing and communication space. To learn more about the dotCOMM Awards and explore the full list of champions, visit www.dotcommawards.com.

###

Media Contact
Tanya Rodante
Director of Global Communication
[email protected]

Expanding Availability of Diabetes Medical Education Programme for Healthcare Providers

Gothenburg, Sweden (PR NEWSWIRE) — July 13, 2022 — Glooko AB (“Glooko”) today announced, in partnership with the Diabetes Technology Network (DTN)/ Association of British Clinical Diabetologists (ABCD), the expansion into Ireland of Academy, the company’s online medical education programme for clinicians who treat people with diabetes. Originally inspired after discussions with the National Health Service England (NHSE) as part of its effort to ensure all healthcare professionals learn uniformly about technology, the programme will help clinicians further increase their knowledge and stay current on the ever-growing assortment of new diabetes technologies.

According to the International Diabetes Federation, Ireland, with a population of just five million people, is ranked 7th in the world for diabetes-related health expenditure per person. For people with diabetes and their healthcare providers, managing the myriad technologies like glucose monitors and insulin pumps, and the data volumes accompanying these technologies, is a well-established challenge. Technology tools like web-based programs, telehealth, mobile apps and remote monitoring are improving users’ accessibility and connectivity, but adoption of these innovations can be slow and complicated.

Academy focuses exclusively on diabetes health technology and education. The programme includes an extensive range of online courses for healthcare providers (HCPs) to increase expertise and mastery of these technologies, to help deploy them to people with diabetes. All courses are accessed through the Glooko® platform or the ABCD website.

Ireland is the second country to implement Academy in Glooko’s plans to provide the program globally. Since launching in the UK in October of 2020, over 1,000 clinicians across more than 300 clinics have registered for the programme, with more than 750 Continuing Professional Development (CPD) certificates awarded.

“We are extremely pleased with the successful adoption of Academy in the UK,” said Russ Johannesson, CEO of Glooko. “We are particularly excited to continue our expansion and offer the programme in Ireland. Our goal is to not only equip primary care and specialist HCPs with the technological skill set relevant to their professional development, but to also support them in building a wider range of capabilities, as treating chronic conditions moves increasingly towards a more digital world.”

Pratik Choudhary, Professor of Diabetes at University of Leicester, Professor/Honorary Consultant in Diabetes and Chair of DTN UK, stated, “Given the rapidly changing landscape of diabetes technologies, it is very important for healthcare professionals to have a trusted resource for training. The Diabetes Technology Network UK is quite pleased to be able to bring the training of Academy to Ireland and support healthcare professionals using the latest diabetes technology.”

The programme is available to all diabetes healthcare professionals in Ireland at no cost and was funded in part via sponsorships from global industry partners like AgaMatrix, Dexcom, Lilly, mylife Diabetescare, Novo Nordisk and Roche. Production was provided by DigiBete (DigiBete Global, Leeds, UK), which remains actively involved in Academy. The curriculum covers the majority of the diabetes devices and technologies, and HCPs that complete the programme will receive CPD accreditation as well as DTN UK/ABCD certification.

Glooko is committed to incorporating newly-developed, online immersive education experiences that complement the Company’s portfolio of industry-leading digital health solutions. Academy is part of Glooko’s global mission to enhance the lives of people with chronic conditions by connecting them with their HCPs and equipping both with the tools needed to achieve improved outcomes.

For more information: go.glooko.com/academy

Sources:
1. International Diabetes Federation Diabetes Atlas (2021)
2. https://worldpopulationreview.com/countries/ireland-population

About Glooko
Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations. For more information, please visit glooko.com.

###

Media Inquiries
Tanya Rodante
Director of Global Communication, Glooko
[email protected]